EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Translation dysregulation in cancer as a source for targetable antigens

Chen Weller, Osnat Bartok, Christopher S McGinnis, Heyilimu Palashati, Tian-Gen Chang, Dmitry Malko, Merav D Shmueli, Asuteka Nagao, Deborah Hayoun, Ayaka Murayama, Yuriko Sakaguchi, Panagiotis Poulis und 35 weitere

Cancer Cell · 2025-05 · 43 (5) · 823-840.e18

DOI: 10.1016/j.ccell.2025.03.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-05. Verfasst von Chen Weller und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel. Hauptthemen laut MEDLINE: Protein Biosynthesis, Neoplasms, Antigens, Neoplasm. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant peptides presented by major histocompatibility complex (MHC) molecules are targets for tumor eradication, as these peptides can be recognized as foreign by T cells. Protein synthesis in malignant cells is dysregulated, which may result in the generation and presentation of aberrant peptides that can be exploited for T cell-based therapies. To investigate the role of translational dysregulation in immunological tumor control, we disrupt translation fidelity by deleting tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) in tumor cells and characterize the downstream impact on translation fidelity and immunogenicity using immunopeptidomics, genomics, and functional assays. These analyses reveal that TYW2 knockout (KO) cells generate immunogenic out-of-frame peptides. Furthermore, Tyw2 loss increases tumor immunogenicity and leads to anti-programmed cell death 1 (PD-1) checkpoint blockade sensitivity in vivo. Importantly, reduced TYW2 expression is associated with increased response to checkpoint blockade in patients. Together, we demonstrate that defects in translation fidelity drive tumor immunogenicity and may be leveraged for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein BiosynthesisNeoplasmsAntigens, NeoplasmHumansAnimalsMiceCell Line, TumorImmunotherapyProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

cancer immunopeptidomeimmune checkpoint blockadeneoantigensnon-canonical peptidestranslation fidelity

Substanzen

Antigens, NeoplasmProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Department of Pathology, Stanford University, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
  • Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo 113-8656, Japan.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • Intramural NIH HHS
  • European Research Council
  • Burroughs Wellcome Fund
  • Israel Science Foundation
  • Horizon 2020
  • European Commission

Zitieren

APA

Weller, C., Bartok, O., McGinnis, C. S., Palashati, H., Chang, T. G., Malko, D., Shmueli, M. D., Nagao, A., Hayoun, D., Murayama, A., Sakaguchi, Y., Poulis, P., Khatib, A., Erlanger Avigdor, B., Gordon, S., Cohen Shvefel, S., Zemanek, M. J., Nielsen, M. M., Boura-Halfon, S., …, & Samuels, Y. (2025). Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell, 43(5), 823-840.e18. https://doi.org/10.1016/j.ccell.2025.03.003

Vancouver

Weller C, Bartok O, McGinnis CS, Palashati H, Chang TG, Malko D, et al. Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell. 2025;43(5):823-840.e18. doi:10.1016/j.ccell.2025.03.003

BibTeX
@article{Weller2025,
  author = {Weller, Chen and Bartok, Osnat and McGinnis, Christopher S and Palashati, Heyilimu and Chang, Tian-Gen and Malko, Dmitry and Shmueli, Merav D and Nagao, Asuteka and Hayoun, Deborah and Murayama, Ayaka and Sakaguchi, Yuriko and Poulis, Panagiotis and Khatib, Aseel and Erlanger Avigdor, Bracha and Gordon, Sagi and Cohen Shvefel, Sapir and Zemanek, Marie J and Nielsen, Morten M and Boura-Halfon, Sigalit and Sagie, Shira and Gumpert, Nofar and Yang, Weiwen and Alexeev, Dmitry and Kyriakidou, Pelgia and Yao, Winnie and Zerbib, Mirie and Greenberg, Polina and Benedek, Gil and Litchfield, Kevin and Petrovich-Kopitman, Ekaterina and Nagler, Adi and Oren, Roni and Ben-Dor, Shifra and Levin, Yishai and Pilpel, Yitzhak and Rodnina, Marina and Cox, Jürgen and Merbl, Yifat and Satpathy, Ansuman T and Carmi, Yaron and Erhard, Florian and Suzuki, Tsutomu and Buskirk, Allen R and Olweus, Johanna and Ruppin, Eytan and Schlosser, Andreas and Samuels, Yardena},
  title = {Translation dysregulation in cancer as a source for targetable antigens},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {5},
  pages = {823--840.e18},
  doi = {10.1016/j.ccell.2025.03.003}
}
Kostenlos starten →